The bill amends Kansas law concerning controlled substances by updating the effective date for certain provisions from 2024 to 2025. It introduces new definitions related to the administration, dispensing, and distribution of controlled substances, including terms such as "administer," "agent," "controlled substance analog," and "electronic prescription." The bill clarifies the roles of practitioners, mid-level practitioners, and dispensers, ensuring that these definitions align with current practices. Additionally, it updates the list of controlled substances in Schedule IV, detailing specific drugs like alprazolam, diazepam, and lorazepam, which have potential for abuse and depressant effects on the central nervous system.

Moreover, the bill includes new legal language that allows for the approval of crystalline polymorph psilocybin as a pharmaceutical composition by the FDA, requiring the Attorney General to certify this approval to the Secretary of State within seven days for publication in the Kansas register. It also specifies the regulation of certain substances, including lorcaserin and various stimulants, under specific conditions, with provisions for expiration based on federal law changes. The bill repeals existing statutes related to the regulation of certain substances, reflecting a modernization of the state's approach to controlled substances in response to evolving federal regulations and potential therapeutic uses. The act will take effect upon publication in the statute book.

Statutes affected:
As introduced: 65-4101, 65-4111
As Amended by House Committee: 65-4111, 65-4101